Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Radiation Oncology

Tumour Site

Urothelial Cancer

Presenters

Himani Manchala

Citation

Annals of Oncology (2020) 31 (suppl_6): S1319-S1324. 10.1016/annonc/annonc357

Authors

H. Manchala1, R. Malladi2

Author affiliations

  • 1 Radiation Oncology, MNJ Institute of Oncology and RCC, 500004 - Hyderabad/IN
  • 2 Radiation Oncology, MNJ Institute of Oncology and RCC, 500004 - HYDERABAD/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 205P

Background

The standard care for muscle invasive bladder carcinoma (MIBC) in the United States for a long time was radical cystectomy where as in Europe, it is radical radiotherapy or multidrug regimen neoadjuvant chemotherapy followed by radiotherapy. In spite of the importance in terms of incidence, prognosis and cost, bladder cancer research remains significantly underfunded so the studies and data on organ preservation in MIBC in India are less explored.

Methods

We analyzed the data of 30 patients of MIBC from 2016-2018 who underwent primary transurethral resection of bladder tumour (TURBT) followed by IMRT with 64.8 Gy and weekly cisplatin at dose of 40 mg/ m2 with median follow up of 10 months. The role of various factors like tumour stage, histopathology, grade, complete TURBT, obstructive uropathy on locoregional response and disease free survival was evaluated. Local reactions evaluated using CTCAE criteria version 5.0. Statistical analysis was done using SPSS version 23.0.

Results

Table: 205P

Demographic and disease characteristics

Age Median – 68 Yrs Range – 52 - 80 Yrs
Sex Male – 86.7% (n=26) Female – 13.3% (n=4)
Turbt Complete – 33.3% (n=10) Incomplete – 66.7% (n=20)
Histopathology Transitional – 86.6%(n=26) Squamous – 6.7% (n=2) Adeno CA – 6.7% (n=2)
Grade Grade I – 6.7% (n=2) Grade II – 26.6% (n=8) Grade III - 66.7% (n=20)
Tumour Stage T2 – 53.3 % (n=16) T3 – 33.3 % (n=10) T4 – 13.4 % (n=4)
Obstructive Uropathy Present – 33.3 % (n=10) Absent – 66.7% (n=20)
Locoregional Response Complete – 73.3% (n=22) Partial – 20% (n=6) Progression – 6.7% (n=2)

After the treatment, the complete locoregional response (LRR) was 73.3%. Early (T2 stage) tumours (p= 0.043) and patients without obstructive uropathy (p= 0.039) have shown significant LRR. Patients with complete TURBT, Low grade tumours shown increased response though statistically not significant. The overall disease free survival in this study for the preserved bladder patients is 53.3%. Patients without obstructive uropathy have shown significant DFS of 70% (p=0.026). Improved DFS of patients with T2 stage tumours (75%), complete TURBT (60%), low grade tumours was observed though statistically not significant. GU toxicities like dysuria, burning micturition in 40% of patients, increased frequency of micturition in 20% of patients, gastro intestinal toxicities like constipation (40%), pain abdomen (6.7%) were observed during followup and all these are grade I,II and managed well with supportive treatment.

Conclusions

Bladder preservation in more than 70% of patients in this study supports the general concept of organ sparing treatment in oncology. The high response rate and DFS were observed in south Indians with complete TURBT, early stage tumours, no obstructive uropathy and low grade tumours. The genito urinary & gastro intestinal toxicities are comparatively less, probably in view of using IMRT technique and single agent cisplatin.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Dr Himani Manchala.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.